Recent studies have reported non-inferior outcomes for transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) in intermediate-risk patients. However, a comparison of outcomes among TAVI patients depending upon the surgical risk score has not been performed in a large study. Our aim was to compare the outcomes of TAVI in low-, intermediate-, and high-risk patients, to ascertain if the morbidity and mortality is related to the patient's risk profile or the procedure itself. 
Introduction
Transcatheter aortic valve implantation (TAVI) has become the default approach for patients with severe aortic stenosis (AS) who are either inoperable or at high risk for surgical aortic valve replacement (SAVR). Evidence relating to the superiority of TAVI over medical therapy in the high-risk patients comes from the PARTNER Cohort B trial 1 and the Core Valve United States Pivotal Trial Extreme-Risk study. 2 Despite providing a mortality benefit, TAVI in high-risk patients is associated with procedure related complications, stroke and vascular bleeding. One would expect that these complications be related to the patient's underlying comorbidities and not to the procedure itself. 
Methods
This systematic review and meta-analysis are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. 3 
Study eligibility
We performed a search for studies looking at outcomes of low to intermediate and high-risk patients undergoing TAVI. We included studies that compared TAVI outcomes in low-, intermediate-, and high-risk cohorts. We included studies using STS and/or Logistic EuroSCORE to define surgical risk in AS patients. Low, intermediate, and high risk were defined as STS score of <4%, 4-8%, and >8%, respectively. Similarly, low, intermediate, and high risk were defined as logistic EuroSCORE of <10%, 10-20%, and >20%, respectively. In the case of any conflict, we divided the data according to the risk score which was used in the original study. Device success was defined according to the Valve Academic Research Consortium-2 (VARC-2) definition as the absence of procedural mortality and correct positioning of a single prosthetic heart valve into the proper anatomical location and intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, and no moderate or severe prosthetic valve regurgitation). 4 We included comparative studies of any design (randomized control trials, cohort, case-control, and cross-sectional). Eligible studies had to provide documentation of the essential features of patients and mean or median risk scores. Included studies also had to report significant complications following both procedures. Studies had to report one or more of the following outcomes: mortality, stroke rate, post-procedure aortic regurgitation, the rate of post-procedure permanent pacemaker implantation, post-procedure myocardial infarction, and rate of acute kidney injury. Inclusion was restricted to publications in the English language or when the translation of the foreign language publications was provided. When data were reported from overlapping study samples (e.g. multiple publications from the same group), the most recent study or the one with the highest number of patients was included in the analysis. Single case reports and previous systematic reviews on TAVI were not included.
Data sources and search strategy
A comprehensive search strategy was designed before commencing the search. A thorough computer-based search was performed using Ovid MEDLINE, EMBASE, Google Scholar, and PubMed databases. Search terms included ('transcatheter aorta valve implantation' OR 'transcatheter aortic valve replacement' OR 'tavi' OR tavr AND ('low risk' OR 'intermediate risk')) and (Mortality or Mortalit* or Death*or Fatalit* or Incidence* or Prevalence* or Statistic*). No limit to the start date was applied, and the search was conducted up to 6 May 2017. We hand searched references cited in the previous reviews and relevant articles on TAVI.
Study selection and data extraction
Two reviewers (KS and KC) screened all titles and abstracts independently. This was followed by the full-text review of the selected articles by the same two reviewers. One reviewer (KS) extracted data independently from selected studies using a standardized, pilot-tested, and extraction template. The following data were extracted: study characteristics (author, country, study design, study population, number of participants, and objective of the study), participant characteristics (age and gender), and clinical characteristics (in-hospital mortality, rate of post-procedure myocardial infarction, moderate to severe aortic regurgitation, rate of permanent pacemaker implantation, stroke and acute kidney injury). 
Quality assessment
We assessed publication bias by visual inspection of funnel plots and by calculation of the P-value (one-sided) for Egger's intercept. In case of observational studies, quality of included studies was analysed using a subset of the Tooth et.al.,
5 article titled 'Quality of Reporting of Observational
Longitudinal Research', including only the 23 quality domains relevant to a meta-analysis of observational studies. We assessed biases using classifications of 'low risk of bias' when data for the criterion were reported, 'high risk of bias' when data were not reported, and 'unclear risk of bias' when the criterion was not relevant to the study design. Review Manager (RevMan, Computer program, Version 5.2., Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2012), was used to generate the risk of bias graph. Disagreements between reviewers for classifications were resolved by either consensus or inclusion of a third party.
Statistical analysis
Continuous variables are reported as mean ± standard deviation, whereas skewed data are described as median ± interquartile range. The measure for estimating the common effect across the included studies was the odds ratio (OR) for binary outcomes and the mean difference for continuous outcomes. Categorical variables are reported using ORs with 95% confidence intervals (CIs). Heterogeneity between studies was assessed by a combination of the I 2 statistic, Cochran's Q test, and observation of the data for each outcome. The random effect model was used in case of significant heterogeneity (I 2 > _40) and the fixed effect model was used when heterogeneity was low (I 2 <40). Significant interaction between variables was considered when P < 0.05. All calculations were performed using Review Manager software, version 5.2.
Results

Literature identification
The literature search yielded 7861 citations on TAVI, of which 283 citations were from studies involving TAVI performance in low-and intermediate-risk groups ( Figure 1) . Full text was reviewed for 283 shortlisted citations, and 68 articles were chosen for inclusion and exclusion criteria. Of the 68 full-text articles considered for eligibility, five studies compared outcomes in low-, intermediate-, and high-risk group patients undergoing TAVI procedure. [6] [7] [8] [9] [10] We included five studies [6] [7] [8] [9] [10] that provided comparative data on low-, intermediate-, and high-risk group patients undergoing TAVI.
Other than two studies, 9,10 all included studies were from Europe.
The basic characteristics of the included studies are shown in Table 1 . In summary, a total of 4931 patients underwent TAVI of which 920, 2414, and 1597 patients were in low-, intermediate-, and high-risk groups, respectively. One study 7 used self-expandable valve alone, another only balloon-expandable valve (Edwards Sapien 3), 10 and both self-expandable and balloon-expandable valves were used in rest of the three studies. The main access route was transfemoral and transapical followed by transaortic and subclavian access ( Table 2) .
The incidence of significant comorbidities in the three groups is shown in Table 3 . The prevalence of previous coronary artery bypass surgery, presence of peripheral vascular disease and known chronic obstructive pulmonary disease was much higher in the high-risk group. The history of stroke was also higher in the high-risk group. Table 4 . In this table, we also added data from the three large randomized trials of TAVI involving intermediate risk patients.
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Quality assessment
Risk of bias assessment showed moderate to high risk of bias in all studies. Three criteria were not well reported across > _75% of studies, including selection, performance, and detection bias (see Supplementary file).
Discussion
In the current systematic review, we assessed results of TAVI in intermediate-risk compared with outcomes of TAVI in high-risk patients. We included five observational studies in the metaanalysis. Our data show that in the real-world majority of patients undergoing TAVI belong to intermediate risk group. We found that 95% of patients undergoing TAVI procedure had a successful deployment of the valve (VARC), and there was no difference in the device success between the intermediate-risk group and the high-risk group. The 30-day all-cause mortality was significantly lower in the intermediate-risk group compared with the high-risk group. There was no significant difference in the post-procedure stroke rate and permanent pacemaker requirement between the two groups.
We confirm that the early mortality in intermediate-risk patients undergoing TAVI is low which is similar or lower than patients undergoing aortic valve surgery. On the other hand, we noted that 30-day all-cause mortality in high-risk patients undergoing TAVI was 5.6%, which is higher than what has been previously reported by randomized studies. The 30-day all-cause mortality in high-risk patients was 3.3% in the US Core Valve study and 5% in the PARTNER trial. 1, 14 The data from the observational studies demonstrate the effectiveness of a therapy in routine clinical practice. Observational studies, such as those included in the current review, allow for the inclusion of a broader population of patients than is possible in randomized control studies. Hence, the mortality reported in the real-world population is somewhat higher. explanation is that TAVI is now offered to extremely high-risk patients who fail to derive a benefit from TAVI and suffer early and late morbidity because of non-cardiac causes.
There is considerable interest now to find the most appropriate group of patients for TAVI, who will achieve the maximum benefit. This is particularly important when we are expanding the indication of TAVI in the current environment of financial constraints. We noticed in our systematic review that two-third of the patients undergoing TAVI belong to the intermediate group. In this regard, it is important to understand that although patients in the low-and intermediate-risk groups represent a lower risk category than TAVI cohorts in previous high-risk studies, these patients are still among 
the highest-risk quintile of patients with AS who routinely undergo open-heart surgery. 15 The other issue which needs to be taken into consideration is that currently employed surgical scores (STS and EuroScore) do not take into considerations other clinical factors such as; patients frailty, extreme calcification of the aorta and medical issues like dementia or cancer, which may affect the overall survival of the patient post-surgery. We did not notice any significant difference with regards to device success, stroke and pacemaker requirement between the intermediate-risk and the high-risk patients undergoing TAVI. This finding raises a hypothesis that the complications of stroke and pacemaker are related to the technical factors and device technology. On the other hand, mortality is related to patient's comorbidities.
The current systematic review has some limitations. First of all, the publication bias can affect the results. The lack of patient level data and combining the results for balloon expandable and selfexpandable valves can reduce the accuracy of results. Combining the two different types of valves could influence the rate of pacemaker implantation. Also, we did not have information separately for transapical and transfemoral approach. Transapical approach of TAVI has been known to be associated with higher complications. Finally, the patients with lower risk score may have other medical illnesses that made them unsuitable for SAVR.
This study confirms that majority of TAVI procedure can be performed in relatively lower risk group patients with 95% success and very low mortality. However, majority of these patients despite being 'low-risk' had STS score above 5%. Furthermore, our study raises assumption that while mortality in TAVI depends upon patient characteristics, major complications may be related to technical factors. 
